Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px
Document › Details

Agilent Technologies Inc.. (9/29/16). "Press Release: Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics". Santa Clara, CA & Guangzhou.

Region Region China
Organisation Organisation Burning Rock (CN)
Products Product SureSelect Target Enrichment System
  Product 2 cancer test, molecular diagnostics
Index term Index term Burning Rock (CN)–Agilent: molecular diagnostics, 201609– collab developm of cancer MDx by BR using Agilent SureSelect target enrichment system
Person Person Thaysen, Jacob (Agilent 201411 VP + President of DGG business unit joined Agilent via acquisition of Dako)
     


Companies Collaborate in Their Aim to Accelerate Accurate Diagnosis


Agilent Technologies Inc. (NYSE: A) and Burning Rock today announced they have signed an agreement under which Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system.

Agilent is the leading provider of target enrichment for next-generation DNA sequencing. Target enrichment saves researchers time and resources by enabling them to focus on regions of interest rather than looking at the entire genome. Burning Rock is a fast-growing company focused on developing cancer diagnostics based on DNA sequencing.

"As the leader in molecular cancer diagnosis in China, Burning Rock is very pleased to partner with Agilent, a global leader in diagnostics and genomics," said Yusheng Han, the founder and chief executive officer of Burning Rock. "Collaboration between our two companies will provide additional high-quality molecular diagnostic solutions based on next-generation sequencing, including non-invasive testing, relapse monitoring, early-stage diagnosis and cancer susceptibility."

Fast and accurate cancer diagnoses are becoming increasingly important in China, with its extensive population and growing focus on advancing human health.

"We are excited to partner with Burning Rock to accelerate accurate diagnosis of cancer for patients in China," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "We believe that target enrichment and next-generation sequencing have a vital role to play in personalizing medicine and ultimately delivering treatments tailored to the individual. This is especially so for complex diseases such as cancer."

Burning Rock plans to register its molecular diagnostic kit with the China Food and Drug Administration. The company believes the kit could become the first CFDA-approved capture sequencing-based cancer diagnostic assay in the Chinese market.


About Burning Rock

Burning Rock is headquartered in Beijing, China, and is a diagnostics company committed to the field of molecular testing to improve oncology patients' individualized treatment guidance. It offers research and commercialized clinical laboratory services mainly through bioinformatics on next-generation sequencing platforms. Burning Rock has a state-of-the-art molecular and pathological examination platform and has developed a series of testing solutions. To learn more, visit www.brbiotech.com.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenue of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

# # #

Contact:

Victoria Wadsworth-Hansen
Agilent Technologies, Inc.
+1 408 553 2005
+45 2933 6980
victoria.wadsworth-hansen@agilent.com

Pan Yingying
Burning Rock
+86 21 6029 3721
yingying.pan@brbiotech.com

   
Record changed: 2016-10-20

Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px download




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 40